Pragmatic methods for reviewing exceptionally large bodies of evidence: systematic mapping review and overview of systematic reviews using lung cancer survival as an exemplar.
Lung cancer
Overview of reviews
Prognostic factors
Prognostic research
Systematic review
Journal
Systematic reviews
ISSN: 2046-4053
Titre abrégé: Syst Rev
Pays: England
ID NLM: 101580575
Informations de publication
Date de publication:
16 07 2019
16 07 2019
Historique:
received:
04
12
2018
accepted:
02
07
2019
entrez:
18
7
2019
pubmed:
18
7
2019
medline:
21
8
2020
Statut:
epublish
Résumé
Lung cancer (LC) is the most common cause of cancer death in the world and associated with significant economic burden. We conducted a review of published literature to identify prognostic factors associated with LC survival and determine which may be modifiable and could be targeted to improve outcomes. The exceptionally large volume of LC prognostic research required a new staged approach to reviewing the literature. This comprised an initial mapping review of existing reviews or meta-analyses, based on titles and abstracts, followed by an overview of systematic reviews evaluating factors that independently contribute to lung cancer survival. The overview of reviews was based on full text papers and incorporated a more in-depth assessment of reviews evaluating modifiable factors. A large volume of published systematic reviews and meta-analyses were identified, but very few focused on modifiable factors for LC survival. Several modifiable factors were identified, which are potential candidates for targeted interventions aiming to improve cancer outcomes. The mapping review included 398 reviews, of which 207 investigated the independent effect of prognostic factors on lung cancer survival. The most frequently evaluated factors were novel biomarkers (86 biomarkers in 138 reviews). Only 15 modifiable factors were investigated in 20 reviews. Those associated with significant survival improvement included normal BMI/less weight loss, good performance status, not smoking/quitting after diagnosis, good pre-treatment quality of life, small gross volume tumour, early-stage tumour, lung resection undertaken by a thoracic/cardiothoracic surgeon, care being discussed by a multidisciplinary team, and timeliness of care. The study utilised a novel approach for reviewing an extensive and complicated body of research evidence. It enabled us to address a broad research question and focus on a specific area of priority. The staged approach ensured the review remained relevant to the stakeholders throughout, whilst maintaining the use of objective and transparent methods. It also provided important information on the needs of future research. However, it required extensive planning, management, and ongoing reviewer training.
Identifiants
pubmed: 31311605
doi: 10.1186/s13643-019-1087-4
pii: 10.1186/s13643-019-1087-4
pmc: PMC6631880
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
171Références
Int J Technol Assess Health Care. 2009 Jul;25 Suppl 1:182-95
pubmed: 19534840
PLoS Med. 2013;10(2):e1001380
pubmed: 23393429
Milbank Q. 2016 Sep;94(3):485-514
pubmed: 27620683
Chest. 2002 Sep;122(3):1037-57
pubmed: 12226051
Br J Cancer. 2015 Mar 31;112 Suppl 1:S92-107
pubmed: 25734382
Syst Rev. 2014 Dec 03;3:140
pubmed: 25466903
Eur J Cancer. 2013 Jun;49(9):2187-98
pubmed: 23453935
Syst Rev. 2015 Dec 22;4:183
pubmed: 26693720
J Clin Epidemiol. 2008 Jun;61(6):552-60
pubmed: 18471659
J Clin Epidemiol. 2016 Nov;79:120-129
pubmed: 27387966
Syst Rev. 2013 Sep 05;2:71
pubmed: 24007720
BMC Med Res Methodol. 2016 Aug 26;16(1):108
pubmed: 27561872
Health Technol Assess. 2009 Jan;13(5):iii, xi-xiii 1-219
pubmed: 19128541
Syst Rev. 2017 Nov 21;6(1):231
pubmed: 29162130
J Thorac Oncol. 2016 Jul;11(7):1040-50
pubmed: 27013405
BMC Med Res Methodol. 2012 Apr 24;12:56
pubmed: 22530717
BMJ. 2001 Jul 28;323(7306):224-8
pubmed: 11473921
Syst Rev. 2012 Feb 10;1:10
pubmed: 22587960
BMC Med Res Methodol. 2011 Feb 03;11(1):15
pubmed: 21291558
PLoS Med. 2013;10(2):e1001381
pubmed: 23393430
Eval Health Prof. 2002 Mar;25(1):12-37
pubmed: 11868442
Ther Adv Med Oncol. 2011 May;3(3):127-38
pubmed: 21904576
BMJ. 2013 Feb 05;346:e5595
pubmed: 23386360
BMJ. 2013 Feb 05;346:e5793
pubmed: 23386361
Syst Rev. 2018 Oct 12;7(1):159
pubmed: 30314530
Stat Med. 2015 Jul 30;34(17):2481-96
pubmed: 25924725
J Thorac Oncol. 2008 Jul;3(7):781-92
pubmed: 18594326
Syst Rev. 2017 Jul 18;6(1):145
pubmed: 28720141
Ann Intern Med. 2013 Feb 19;158(4):280-6
pubmed: 23420236
Br J Cancer. 2012 Mar 27;106(7):1262-7
pubmed: 22415239
Syst Rev. 2012 Jul 09;1:32
pubmed: 22775986
Syst Rev. 2018 Mar 1;7(1):39
pubmed: 29490699
PLoS One. 2015 May 01;10(5):e0126608
pubmed: 25933397
J Clin Epidemiol. 2016 Feb;70:38-44
pubmed: 26261004
J Clin Epidemiol. 2009 Oct;62(10):1013-20
pubmed: 19230606